Patents Assigned to Dana-Farber Cancer Institute
  • Publication number: 20250136599
    Abstract: Compounds of formula (I), formula (I), processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: November 15, 2024
    Publication date: May 1, 2025
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan Siegel, Franziska Siegel, Volker Schulze, Markus Berger, Keith Graham, Detlev Sülzle, Ulf Bömer, Daniel Korr, Jens Schröder, Ursula Mönning, Michael Niehues, Matthew Meyerson, Heidi Greulich, Bethany Kaplan
  • Publication number: 20250127783
    Abstract: Disclosed are methods of treating diseases or disorders mediated by dysregulated CDK4/6 and/or Pin 1 activity comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more Pin1 inhibitors, or a pharmaceutically acceptable salt or salts thereof
    Type: Application
    Filed: September 23, 2022
    Publication date: April 24, 2025
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., BETH ISRAEL DEACONESS MEDICAL CENTER, INC., YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Shizhong KE, Gerburg WULF, Xiao Zhen ZHOU, Nir LONDON, Wenyi WEI, Kun Ping LU, Nathanael S. GRAY, Behnam NABET
  • Publication number: 20250129435
    Abstract: The present disclosure provides a novel method of diagnosing lymphoma, breast cancer, a lymphoma subtype, or a breast cancer subtype in a patient, and kits for implementing the methods.
    Type: Application
    Filed: October 23, 2024
    Publication date: April 24, 2025
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Edward BRIERCHECK, Fabiola Valvert GAMBOA, Oscar SILVA, Yaso NATKUNAM, Kristen STEVENSON, David WEINSTOCK
  • Patent number: 12281126
    Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds of the present disclosure are inhibitors of kinases (e.g., a cyclin-dependent kinase (CDK) (e.g., CDK7)). The compounds may be selective for inhibiting the activity of a kinase (e.g., CDK7) over certain other kinases (e.g., CDK2, CDK9, CDK12). Also provided are pharmaceutical compositions, kits, methods of use, and uses that involve the compounds. The compounds may be useful in inhibiting the activity of a kinase, down-regulating the transcription of MYC or MCL-1, inhibiting the growth of a cell, inducing apoptosis of a cell, treating a disease, and/or preventing a disease (e.g., proliferative disease, cystic fibrosis).
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: April 22, 2025
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Tinghu Zhang, Nicholas Paul Kwiatkowski, Jie Jiang, Mingfeng Hao, Zhixiang He
  • Patent number: 12282014
    Abstract: The present invention provides methods of screening for compounds that interfere with the interaction between ERG. ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins are also provided.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: April 22, 2025
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Cigall Kadoch, Gabriel Sandoval, William C. Hahn
  • Publication number: 20250122210
    Abstract: The disclosure relates to compounds that act as inhibitors of KRAS; pharmaceutical compositions comprising the compounds; and methods of treating or preventing disorders, including cancer and other proliferation diseases.
    Type: Application
    Filed: June 29, 2022
    Publication date: April 17, 2025
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jianwei Che, Guangyan Du, Tinghu Zhang, Wenzhi Ji
  • Patent number: 12275731
    Abstract: Disclosed are compounds that possess inhibitory activity against LRRK2. Also disclosed are pharmaceutical compositions containing the compounds and methods of using the compounds to treat diseases and disorders including neurodegenerative diseases and disorders such as Parkinson's disease, and brain cancer (e.g., gliomas and glioblastomas).
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: April 15, 2025
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., VORONOI INC.
    Inventors: Nathanael S. Gray, John Hatcher, Jieun Choi, Hwangeun Choi, Eunhwa Ko, Namdoo Kim
  • Patent number: 12268739
    Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease. (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: April 8, 2025
    Assignees: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: David J. Dowling, Ofer Levy, Francesco Borriello, David A. Scott, Spencer E. Brightman
  • Patent number: 12268748
    Abstract: The present disclosure provides, in some aspects, nucleic acid nanostructures covalently linked to oligolysine-PEG copolymers.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: April 8, 2025
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: William M. Shih, Zhao Zhao, Frances M. Anastassacos
  • Patent number: 12263166
    Abstract: The disclosure relates to methods for treating cancers (e.g., cancers having a BRCA1 and/or BRCA2 mutation(s)) by administering to the subject an effective amount of a ubiquitin-specific protease 1 (USP1) inhibitor.
    Type: Grant
    Filed: July 7, 2022
    Date of Patent: April 1, 2025
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Alan D'Andrea, Kah Suan Lim
  • Patent number: 12258560
    Abstract: The present invention provides circularized RNA and methods of making and using same.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: March 25, 2025
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Michael Goldberg, Ellese Carmona
  • Patent number: 12258409
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Grant
    Filed: September 22, 2022
    Date of Patent: March 25, 2025
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
  • Patent number: 12258378
    Abstract: This invention is directed to engineered cells and methods for using the same. In embodiments, the engineered cell comprises a nucleic acid encoding a chimeric antigen receptor and a polypeptide, wherein the chimeric antigen receptor is specific for two or more antigens on the surface of a cancer cell, and wherein the polypeptide comprises an antibody or fragment thereof that can be secreted from the engineered cell.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: March 25, 2025
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Quan Karen Zhu, Emily Kuiper
  • Patent number: 12258323
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: March 25, 2025
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • Publication number: 20250092114
    Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: April 11, 2024
    Publication date: March 20, 2025
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Matthew Vanneman, Gordon Freeman
  • Publication number: 20250084453
    Abstract: Described and featured are compositions, a system and methods for identifying and selecting substrates of E3 ligases by ubiquitin biotinylation. The components of the compositions, system and methods are ubiquitin- and interaction-specific, thereby providing the enrichment and identification of endogenous or exogenous E3 ligase substrate molecules that are proximally ubiquitinated and biotinylated by components designed to interact both physically and functionally in the compositions, system and methods. The compositions, system and methods are useful and advantageous for identifying and selecting E3 ligase substrates (and/or associated molecules) that are modulated or induced by other agents, such as immunomodulatory imide agents (IMiDs), molecular glues and bifunctional proteolysis targeting chimeras (PROTAC®s).
    Type: Application
    Filed: November 26, 2024
    Publication date: March 13, 2025
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: William Sellers, Hai-Tsang Huang
  • Patent number: 12246004
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of microsatellite unstable cancers. In particular, the instant disclosure provides for identification of a cancer as exhibiting microsatellite instability (MSI) and/or impaired mismatch repair (MMR), and selection and/or administration of an inhibitor of the WRN helicase as a therapeutic agent for such a cancer and/or subject having or at risk of developing such a cancer.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: March 11, 2025
    Assignees: THE BROAD INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Francisca Vazquez, Adam Bass, Tsukasa Shibue, Edmond Chan, James McFarland, Mahmoud Ghandi, Aviad Tsherniak
  • Publication number: 20250074890
    Abstract: Described are the compounds, compositions and methods of treating a disease or disorder characterized by aberrant B-cell lymphoma 6 (BCL6) activity.
    Type: Application
    Filed: August 1, 2022
    Publication date: March 6, 2025
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Lyn Howard Jones, Jianwei Che, Huang Huang, Nikki Kong, Silas Ferrao, Yingpeng Liu, Justin Cruite
  • Patent number: 12239646
    Abstract: Bacterial species and the associated microbiome persist in tumors and metastases. Antibiotic treatment selectively reduces microbiome-induced tumor growth and can advantageously be included in treatment regimens. Accordingly, the present disclosure relates to, for example, the diagnosing cancer in a subject and providing identifying an effective treatment regimen for the subject.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: March 4, 2025
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Matthew Meyerson, Susan Bullman
  • Patent number: RE50319
    Abstract: The present application provides, in some aspects, methods of treating cancers, such as homologous recombination (HR)-deficient cancers. In some embodiments, the disclosure provides a method for treating cancer by administering to a subject a compound of Formula (I):(I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 10, 2022
    Date of Patent: March 4, 2025
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D'Andrea, Raphael Ceccaldi, Jia Zhou